News Achilles Therapeutics plc

Equities

ACHL

US00449L1026

Market Closed - Nasdaq Other stock markets 16:00:00 2024-04-26 EDT			5-day change	1st Jan Change
0.76 ^USD	-1.86%		-2.93%	-14.51%

04-05	Piper Sandler Downgrades Achilles Therapeutics to Neutral From Overweight, Cuts Price Target to $2 From $8	MT
04-05	Chardan Capital Adjusts Achilles Therapeutics Price Target to $6 From $11, Maintains Buy Rating	MT

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Piper Sandler Downgrades Achilles Therapeutics to Neutral From Overweight, Cuts Price Target to $2 From $8	04-05	MT
Chardan Capital Adjusts Achilles Therapeutics Price Target to $6 From $11, Maintains Buy Rating	04-05	MT
ADRs Close Lower; Moatable Inc. Declines 33.3%	04-04	DJ
Syncona notes investee Achilles's annual loss narrows	04-04	AN
Achilles Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Recent Business Highlights	04-04	AQ
Achilles Therapeutics plc Reports Earnings Results for the Full Year Ended December 31, 2023	04-04	CI
Achilles Therapeutics plc Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	04-04	CI
Achilles Therapeutics Provides Interim Phase I/IIa Update on Clonal Neoantigen Reactive T Cells in Advanced NSCLC and Melanoma Including First Patients Dosed with Enhanced Host Conditioning	04-04	AQ
Achilles Therapeutics plc Provides Interim Phase I/IIa Update on Clonal Neoantigen Reactive T Cells in Advanced NSCLC and Melanoma Including First Patients Dosed with Enhanced Host Conditioning	04-04	CI
Achilles Therapeutics to Present at the 10th Annual Immuno-Oncology 360 Conference	02-05	AQ
Achilles Therapeutics Announces Publication of Nature Cancer ‘Comment’ on Strategy for Improved Neoantigen Immunogenicity Prediction	12-18	AQ
BofA Securities Downgrades Achilles Therapeutics to Underperform From Buy, Price Target is $0.50	12-14	MT
Syncona notes investee company's quarterly loss	11-14	AN
Achilles Therapeutics Reports Third Quarter 2023 Financial Results and Recent Highlights	11-13	AQ
Achilles Therapeutics plc Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-13	CI
Achilles Therapeutics Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement	23-09-22	AQ
Syncona's portfolio Achilles Therapeutics net loss narrows	23-08-04	AN
Achilles Therapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights	23-08-04	AQ
Achilles Therapeutics : Corporate Presentation – August 2023	23-08-04	PU
Achilles Therapeutics plc Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-04	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Achilles Therapeutics plc

Equities

ACHL

US00449L1026

Summary

Filters